CD8A and melanoma: In contrast to the weak immune response induced by VSV-gp100, intranasal injection of a recombinant VSV expressing the human dopachrome tautomerase (hDCT) activated both CD4+ and CD8+ DCT-specific T cell responses in a murine melanoma model [117].